Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Abstract Background Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these tumors acquire resistance to KI and patients succumb to their disease. Salvage ther...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Priyanka C. Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L. Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D. Williams, G. Brandon Gunn, Horiana Grosu, Heath D. Skinner, Erich M. Sturgis, Neil Gross, Maria E. Cabanillas
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMJ Publishing Group 2018-07-01
Sarja:	Journal for ImmunoTherapy of Cancer
Aiheet:	Anaplastic thyroid cancer Immunotherapy Salvage Thyroid cancer Lenvatinib Dabrafenib
Linkit:	http://link.springer.com/article/10.1186/s40425-018-0378-y
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!